NeoMET Study in Neoadjuvant Treatment of Breast Cancer (NeoMET)
Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial
Sponsor: Shanghai Jiao Tong University School of Medicine
Terminated
Slow enrollment.
Other terminated trials from Shanghai Jiao Tong University School of Medicine
- Carcinoma, Squamous Cell · Phase PHASE2 · Jul 2023
- Breast Neoplasm · Phase PHASE2 · Jun 2021
- Cognition Disorders · Nov 2019
- Multiple Myeloma · Phase PHASE2/PHASE3 · Dec 2016
- Breast Cancer · Phase PHASE3 · Oct 2015
See all terminations from Shanghai Jiao Tong University School of Medicine
A PHASE2 clinical study on BCT Rate and Safety, this trial is terminated or withdrawn. The trial is conducted by Shanghai Jiao Tong University School of Medicine and has accumulated 10 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
May 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .